Read how a biotech acquisition of a marketed COPD therapy shifts strategy toward funding innovation with steady commercial cash flow.
Key Takeaways
- Zymeworks agreed to buy Theravance’s marketed COPD drug for $929 million
- Deal uses a $350 million note backed by the drug’s future profit share
- Zymeworks will keep existing hospital commercial infrastructure and Viatris community promotion arrangements